Literature DB >> 9705099

An increased concentration of rifampicin bonded to gelatin-sealed Dacron reduces the incidence of subsequent graft infections following a staphylococcal challenge.

M Vicaretti1, W J Hawthorne, P Y Ao, J P Fletcher.   

Abstract

The purpose of this study was to determine if 10 mg/ml rifampicin bonded to gelatin-sealed Dacron (Gelsoft) reduced staphylococcal infection. Grafts soaked in rifampicin were interposed in the left carotid artery of 20 merino sheep and then inoculated with 10(8) colony-forming units of MRSA (10 sheep) or a slime producing Staphylococcus epidermidis (10 sheep). Grafts were harvested at 3 weeks, and perigraft abscess, anastomotic disruption and graft occlusion recorded. Swabs were taken to assess bacterial growth of the perigraft tissues, and external and internal graft surface. Grafts segments were incubated in broth medium. Results were compared with previously published results that used graft that were not soaked in rifampicin (control) and grafts soaked in 1.2 mg/ml rifampicin. A total of 4/50 cultures were positive and significantly reduced for S. epidermidis compared with the control group of 30/50 (P < 0.05) and the 1.2 mg/ml group of 13/45 (P < 0.05). For the methicillin resistant staphylococcus aureus (MRSA) group, 6/40 cultures were positive, which was significantly reduced compared with the control group (38/40, P < 0.05) and the 1.2-mg/ml group (19/32, P < 0.05). In conclusion an increased concentration of rifampicin significantly reduced the incidence of prosthetic vascular graft infection following a challenge of MRSA or S. epidermidis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9705099     DOI: 10.1016/s0967-2109(98)00003-9

Source DB:  PubMed          Journal:  Cardiovasc Surg        ISSN: 0967-2109


  7 in total

Review 1.  Tissue Engineering at the Blood-Contacting Surface: A Review of Challenges and Strategies in Vascular Graft Development.

Authors:  Daniel Radke; Wenkai Jia; Dhavan Sharma; Kemin Fena; Guifang Wang; Jeremy Goldman; Feng Zhao
Journal:  Adv Healthc Mater       Date:  2018-05-07       Impact factor: 9.933

2.  Mupirocin prophylaxis against methicillin-susceptible, methicillin-resistant, or vancomycin-intermediate Staphylococcus epidermidis vascular-graft infection.

Authors:  A Giacometti; O Cirioni; R Ghiselli; L Goffi; C Viticchi; F Mocchegiani; A Riva; F Orlando; V Saba; G Scalise
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

Review 3.  Multidisciplinary Treatment Approach for Prosthetic Vascular Graft Infection in the Thoracic Aortic Area.

Authors:  Takeshiro Fujii; Yoshinori Watanabe
Journal:  Ann Thorac Cardiovasc Surg       Date:  2015-09-08       Impact factor: 1.520

4.  Polycationic peptides as prophylactic agents against methicillin-susceptible or methicillin-resistant Staphylococcus epidermidis vascular graft infection.

Authors:  A Giacometti; O Cirioni; R Ghiselli; L Goffi; F Mocchegiani; A Riva; G Scalise; V Saba
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

5.  Efficacy of quinupristin-dalfopristin in preventing vascular graft infection due to Staphylococcus epidermidis with intermediate resistance to glycopeptides.

Authors:  Andrea Giacometti; Oscar Cirioni; Roberto Ghiselli; Fiorenza Orlando; Federico Mocchegiani; Alessandra Riva; Maria Simona Del Prete; Vittorio Saba; Giorgio Scalise
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

6.  Development and characterisation of a large diameter decellularised vascular allograft.

Authors:  A Aldridge; A Desai; H Owston; L M Jennings; J Fisher; P Rooney; J N Kearney; E Ingham; S P Wilshaw
Journal:  Cell Tissue Bank       Date:  2017-11-29       Impact factor: 1.522

Review 7.  Bacteriophages for the Treatment of Graft Infections in Cardiovascular Medicine.

Authors:  Simon Junghans; Sebastian V Rojas; Romy Skusa; Anja Püschel; Eberhard Grambow; Juliane Kohlen; Philipp Warnke; Jan Gummert; Justus Gross
Journal:  Antibiotics (Basel)       Date:  2021-11-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.